<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736629</url>
  </required_header>
  <id_info>
    <org_study_id>IRB17-1287</org_study_id>
    <nct_id>NCT03736629</nct_id>
  </id_info>
  <brief_title>Azithromycin Treatment for the Airway Microbiome in Asthma</brief_title>
  <official_title>The AZITRAMBA Trial: Azithromycin Treatment for the Airway Microbiome in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to determine whether the bacteria inside the lungs of people with
      asthma can be modified (changed) if they are given an antibiotic and if this change is
      associated with an improvement in asthma symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Control Test (ACT) score change from baseline over 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Score ranging from 0 to 40 indicating the degree of asthma symptoms. Lower score indicating worse asthma symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume (FEV1) change from baseline over 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Volume of air exhaled in 1 second on a forced expiration, indicating the degree of airflow obstruction in asthma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum eosinophils change from baseline over 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of 'eosinophils', an inflammatory cell seen in the airways of people with asthma, indicating the degree of inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum neutrophils change from baseline over 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of 'neutrophils', an inflammatory cell seen in the airways of people with asthma, indicating the degree of inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COMPEX score of asthma severity from baseline over 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>A weighted scoring system that describes asthma symptoms done on a daily basis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiome Shannon alpha-diversity score change from baseline to 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>A measure of the diversity of the bacteria in the sputum or oral sample; that is, how many different types of bacteria are present. This value decreases in severe asthma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiome beta-diversity score change from baseline to 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>A second measure of the diversity of the bacteria in the sputum or oral sample; that is, how many different types of bacteria are present. This value decreases in severe asthma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiome change in relative proportion of top 10 genera from baseline to 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>A measure of how many of the top types of bacteria are present in the sputum or oral sample. Value changes with asthma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Asthma Chronic</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 weeks of placebo capsule once daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 weeks of Azithromycin (250 mg) capsule once daily by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>8 weeks of Azithromycin (250 mg) once daily by mouth</description>
    <arm_group_label>Azithromycin</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (All participants):

          1. Age 18 - 55 years

          2. Able to provide informed consent

          3. Smoking history &lt; 10 pack-years

        Inclusion Criteria for subjects with poorly controlled asthma

          1. Methacholine PC20 &lt; 16 mg/ml or PD 20 &lt; 400 mcg/ml or albuterol response &gt; 12% on FEV1
             after 4 puffs of albuterol

          2. Currently prescribed ICS + LABA

          3. Meet definition for Th2-low asthma: peripheral blood eosinophil count &lt; 300 and
             exhaled nitric oxide level &lt; 30 ppb.

        Exclusion Criteria (All participants)

          1. History of allergy or intolerance to any medications used in this study

          2. Medication exclusions:

               1. Current use of medications that prolong QTc interval

               2. Current use of omalizumab or other ant-IgE therapies

               3. Current use of anti-IL 5 therapies

               4. Current use of anticoagulants

          3. Prednsione or other oral steroids within past 3 months

          4. Pregnancy or lactation, or plans to become pregnant

          5. Other respiratory or inflammatory disorders (e.g., sarcoidosis, emphysema)

          6. Pre-existing liver disease by history

          7. Smoking within the last 6 months

          8. Exacerbation of asthma in past 3 months

          9. Affected by a hearing disorder

         10. Clinically significant medical condition (e.g., heart failure, seizure disorder) which
             may in-crease risk as determined by study investigator

         11. Corrected QT interval &gt; 450 msec. Patients with known cardiac history or prolonged QT
             interval on a screening EKG are excluded given the small but real potential for
             macrolide-related side effects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve White, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steve White, MD</last_name>
    <phone>773-702-2004</phone>
    <email>swhite@medicine.bsd.uchicago.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Spring Maleckar</last_name>
    <phone>773-834-4053</phone>
    <email>smalecka@medicine.bsd.uchicago.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lew Smith, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve White, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Sputum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will share individual participant data that is de-identified available to all qualified investigators</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Upon publication of the major manuscript to be generated from this study. Data will be deposited in an appropriate major database (e.g., sequencing information will be deposited in a genetics bio-bank).</ipd_time_frame>
    <ipd_access_criteria>All qualified investigators who sign appropriate data use agreements and material transfer agreements with the University of Chicago and Northwestern University</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

